Only randomised controlled trials (RCTs) published between January 2020 and October 2025 were included to capture the most recent and clinically relevant evidence regarding the cardiometabolic benefits and risks of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.